[Serum levels of soluble intercellular adhesion molecule 1 in malignant lymphoproliferative disorders].
To investigate the correlation of serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) with clinical situation and treatment outcome in lymphoproliferative disorders. Serum sICAM-1 levels were measured by immunoenzymatic assay. Pre-treatment serum sICAM-1 levels were above normal in 41% (9/22) of multiple myeloma (MM), 53% (17/32) of non-Hodgkin's lymphoma (NHL) and 63% (12/19) of acute lymphocytic leukemia (ALL) patients. Serum sICAM-1 levels in MM were positively correlated with Bataille stages, but were not related to Durie stage. Meanwhile, sICAM-1 levels in NHL were associated with the category of pathology, Ann Arbor stage and B symptom, but were not related to serum LDH levels. sICAM-1 levels were significantly higher in ALL patients complicated with central nervous system leukemia (CNSL) than in those without CNSL. Patients with elevated serum sICAM-1 levels had poorer treatment outcomes. Serum sICAM-1 levels were returned to normal at remission. Measurement of serum sICAM-1 levels in lymphoproliferative disorders patients is helpful for judging the clinical status and treatment outcome.